vs

Side-by-side financial comparison of Penumbra Inc (PEN) and Symbotic Inc. (SYM). Click either name above to swap in a different company.

Symbotic Inc. is the larger business by last-quarter revenue ($630.0M vs $385.4M, roughly 1.6× Penumbra Inc). Penumbra Inc runs the higher net margin — 12.3% vs 0.4%, a 11.9% gap on every dollar of revenue. On growth, Symbotic Inc. posted the faster year-over-year revenue change (29.4% vs 22.1%). Over the past eight quarters, Symbotic Inc.'s revenue compounded faster (21.9% CAGR vs 17.6%).

Penumbra, Inc. is an American medical device company headquartered in Alameda, California. The company was founded by Arani Bose and Adam Elsesser in 2004. It manufactures devices for interventional therapies to treat vascular conditions such as stroke and aneurysm.

Symbotic Inc. is an American robotics warehouse automation company based in Wilmington, Massachusetts.

PEN vs SYM — Head-to-Head

Bigger by revenue
SYM
SYM
1.6× larger
SYM
$630.0M
$385.4M
PEN
Growing faster (revenue YoY)
SYM
SYM
+7.3% gap
SYM
29.4%
22.1%
PEN
Higher net margin
PEN
PEN
11.9% more per $
PEN
12.3%
0.4%
SYM
Faster 2-yr revenue CAGR
SYM
SYM
Annualised
SYM
21.9%
17.6%
PEN

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
PEN
PEN
SYM
SYM
Revenue
$385.4M
$630.0M
Net Profit
$47.3M
$2.6M
Gross Margin
68.0%
21.2%
Operating Margin
15.4%
1.0%
Net Margin
12.3%
0.4%
Revenue YoY
22.1%
29.4%
Net Profit YoY
40.6%
174.9%
EPS (diluted)
$1.20
$0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PEN
PEN
SYM
SYM
Q4 25
$385.4M
$630.0M
Q3 25
$354.7M
$618.5M
Q2 25
$339.5M
$592.1M
Q1 25
$324.1M
$549.7M
Q4 24
$315.5M
$486.7M
Q3 24
$301.0M
$503.6M
Q2 24
$299.4M
$491.9M
Q1 24
$278.7M
$424.3M
Net Profit
PEN
PEN
SYM
SYM
Q4 25
$47.3M
$2.6M
Q3 25
$45.9M
$-3.6M
Q2 25
$45.3M
$-5.9M
Q1 25
$39.2M
$-3.9M
Q4 24
$33.7M
$-3.5M
Q3 24
$29.5M
$-2.5M
Q2 24
$-60.2M
$-2.5M
Q1 24
$11.0M
$-6.6M
Gross Margin
PEN
PEN
SYM
SYM
Q4 25
68.0%
21.2%
Q3 25
67.8%
20.6%
Q2 25
66.0%
18.2%
Q1 25
66.6%
19.6%
Q4 24
66.8%
16.4%
Q3 24
66.5%
12.7%
Q2 24
54.4%
13.7%
Q1 24
65.0%
10.4%
Operating Margin
PEN
PEN
SYM
SYM
Q4 25
15.4%
1.0%
Q3 25
13.8%
-3.5%
Q2 25
12.0%
-6.2%
Q1 25
12.4%
-5.8%
Q4 24
13.6%
-5.1%
Q3 24
11.7%
-4.3%
Q2 24
-27.0%
-5.1%
Q1 24
4.3%
-12.0%
Net Margin
PEN
PEN
SYM
SYM
Q4 25
12.3%
0.4%
Q3 25
12.9%
-0.6%
Q2 25
13.3%
-1.0%
Q1 25
12.1%
-0.7%
Q4 24
10.7%
-0.7%
Q3 24
9.8%
-0.5%
Q2 24
-20.1%
-0.5%
Q1 24
3.9%
-1.6%
EPS (diluted)
PEN
PEN
SYM
SYM
Q4 25
$1.20
$0.02
Q3 25
$1.17
$-0.04
Q2 25
$1.15
$-0.05
Q1 25
$1.00
$-0.04
Q4 24
$0.88
$-0.03
Q3 24
$0.75
$-0.03
Q2 24
$-1.55
$-0.02
Q1 24
$0.28
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PEN
PEN
SYM
SYM
Cash + ST InvestmentsLiquidity on hand
$186.9M
$1.8B
Total DebtLower is stronger
Stockholders' EquityBook value
$1.4B
$663.8M
Total Assets
$1.8B
$3.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PEN
PEN
SYM
SYM
Q4 25
$186.9M
$1.8B
Q3 25
$321.0M
$1.2B
Q2 25
$421.8M
$777.6M
Q1 25
$376.1M
$954.9M
Q4 24
$324.4M
$903.0M
Q3 24
$280.5M
$727.3M
Q2 24
$288.3M
$870.5M
Q1 24
$223.1M
$901.4M
Stockholders' Equity
PEN
PEN
SYM
SYM
Q4 25
$1.4B
$663.8M
Q3 25
$1.4B
$221.3M
Q2 25
$1.3B
$210.8M
Q1 25
$1.2B
$205.4M
Q4 24
$1.2B
$196.5M
Q3 24
$1.1B
$197.2M
Q2 24
$1.2B
$418.7M
Q1 24
$1.2B
$417.1M
Total Assets
PEN
PEN
SYM
SYM
Q4 25
$1.8B
$3.0B
Q3 25
$1.7B
$2.4B
Q2 25
$1.7B
$1.8B
Q1 25
$1.6B
$2.0B
Q4 24
$1.5B
$1.7B
Q3 24
$1.5B
$1.6B
Q2 24
$1.5B
$1.6B
Q1 24
$1.6B
$1.6B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PEN
PEN
SYM
SYM
Operating Cash FlowLast quarter
$86.5M
$191.5M
Free Cash FlowOCF − Capex
$68.0M
FCF MarginFCF / Revenue
17.7%
Capex IntensityCapex / Revenue
4.8%
Cash ConversionOCF / Net Profit
1.83×
73.61×
TTM Free Cash FlowTrailing 4 quarters
$174.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PEN
PEN
SYM
SYM
Q4 25
$86.5M
$191.5M
Q3 25
$58.3M
$530.7M
Q2 25
$44.9M
$-138.3M
Q1 25
$49.0M
$269.6M
Q4 24
$51.1M
$205.0M
Q3 24
$56.5M
$-99.4M
Q2 24
$22.6M
$50.4M
Q1 24
$38.3M
$21.1M
Free Cash Flow
PEN
PEN
SYM
SYM
Q4 25
$68.0M
Q3 25
$42.0M
Q2 25
$29.4M
Q1 25
$35.5M
Q4 24
$45.7M
$197.7M
Q3 24
$51.0M
$-120.1M
Q2 24
$18.1M
$33.5M
Q1 24
$32.5M
$18.6M
FCF Margin
PEN
PEN
SYM
SYM
Q4 25
17.7%
Q3 25
11.8%
Q2 25
8.7%
Q1 25
11.0%
Q4 24
14.5%
40.6%
Q3 24
16.9%
-23.9%
Q2 24
6.0%
6.8%
Q1 24
11.7%
4.4%
Capex Intensity
PEN
PEN
SYM
SYM
Q4 25
4.8%
Q3 25
4.6%
Q2 25
4.6%
Q1 25
4.2%
Q4 24
1.7%
1.5%
Q3 24
1.8%
4.1%
Q2 24
1.5%
3.4%
Q1 24
2.1%
0.6%
Cash Conversion
PEN
PEN
SYM
SYM
Q4 25
1.83×
73.61×
Q3 25
1.27×
Q2 25
0.99×
Q1 25
1.25×
Q4 24
1.52×
Q3 24
1.91×
Q2 24
Q1 24
3.48×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PEN
PEN

Thrombectomy$254.7M66%
Other$130.7M34%

SYM
SYM

Systems$590.3M94%
Operation Services$28.8M5%
Software Maintenance And Support$10.9M2%
Revision Of Prior Period Change In Accounting Principle Adjustment$2.9M0%
Related Party$1.1M0%

Related Comparisons